<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S1247 IS: Pediatric, Adolescent, and Young Adult Cancer Survivorship Research and Quality of Life Act of 2013</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2013-06-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 1247</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130627">June 27, 2013</action-date>
			<action-desc><sponsor name-id="S259">Mr. Reed</sponsor> introduced the
			 following bill; which was read twice and referred to the
			 <committee-name committee-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To improve and enhance research and programs on childhood
		  cancer survivorship, and for other purposes. </official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short
			 title</header><text display-inline="no-display-inline">This Act may be cited as
			 the <quote><short-title>Pediatric, Adolescent, and Young
			 Adult Cancer Survivorship Research and Quality of Life Act of
			 2013</short-title></quote>.</text>
		</section><section id="IDa3a78df48b72400c85ec67d6c9ff7083"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds as follows:</text>
			<paragraph id="ID6dd600bdad79460ab8fd000a5e9b07ec"><enum>(1)</enum><text>An estimated
			 13,500 children and adolescents under age 20 are diagnosed with cancer each
			 year.</text>
			</paragraph><paragraph id="ID487899104efa4c458ed282a3892edb77"><enum>(2)</enum><text>In 1960, only 4
			 percent of children with cancer survived more than 5 years, but by 2011, cure
			 rates have increased to 78 percent for children and adolescents under age
			 20.</text>
			</paragraph><paragraph id="ID2b1fece7525b449da26a520161642b5b"><enum>(3)</enum><text>As of June 2013,
			 there are more than 360,000 childhood cancer survivors living in the United
			 States.</text>
			</paragraph><paragraph id="ID1a79c9b62ed54d3895394bb0ad9e2f6a"><enum>(4)</enum><text>As many as
			 <fraction>2/3</fraction> of childhood cancer survivors are likely to experience
			 at least one late effect of treatment, with as many as <fraction>1/4</fraction>
			 experiencing a late effect that is serious or life-threatening. The most common
			 late effects of childhood cancer are neurocognitive, psychological,
			 cardiopulmonary, endocrine, and musculoskeletal effects and secondary
			 malignancies.</text>
			</paragraph><paragraph id="IDb67ee68547f3471f8be7a427607623b3"><enum>(5)</enum><text>The late effects
			 of cancer treatment may change as treatments evolve, which means that the
			 monitoring and treatment of cancer survivors may need to be modified on a
			 routine basis.</text>
			</paragraph><paragraph id="ID81b6cd1d392d427e8d6775fae265485e"><enum>(6)</enum><text>The Institute of
			 Medicine, in its report on cancer survivorship entitled <term>Childhood Cancer
			 Survivorship: Improving Care and Quality of Life</term>, states that an
			 organized system of care and a method of care for pediatric cancer survivors is
			 needed.</text>
			</paragraph></section><section id="ID23d22c51c7ba4e3daeb3a7b02090bb96"><enum>3.</enum><header>Cancer
			 survivorship programs</header>
			<subsection id="ID60bf96a906f44499b284d578fc4acb5c"><enum>(a)</enum><header>Cancer
			 survivorship programs</header><text>Subpart 1 of part C of title IV of the
			 Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/285">42 U.S.C. 285 et seq.</external-xref>) is amended by adding at the
			 end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id9223B92B1EA64F00AA7D8466D5828620" style="OLC">
					<section id="IDcfc0167f42b145b9b99cb34f052cd296"><enum>417H.</enum><header>Pilot
				programs to explore model systems of care for pediatric cancer
				survivors</header>
						<subsection id="ID11510b9e873e44bd8050b8093d432ca0"><enum>(a)</enum><header>In
				general</header><text>The Secretary may make grants to eligible entities to
				establish pilot programs to develop, study, or evaluate model systems for
				monitoring and caring for childhood cancer survivors.</text>
						</subsection><subsection id="ID709fcccb123b43b3a73f08db30a60e20"><enum>(b)</enum><header>Eligible
				entities</header><text>In this section, the term <term>eligible entity</term>
				means—</text>
							<paragraph id="ID93315a6ef1c2456ab038a26d4319ebee"><enum>(1)</enum><text>a medical
				school;</text>
							</paragraph><paragraph id="IDc1303fec8c1d439493515c2e4d0b899c"><enum>(2)</enum><text>a children’s
				hospital;</text>
							</paragraph><paragraph id="ID753d6660b1ec468ea00a605804bcaa00"><enum>(3)</enum><text>a cancer center;
				or</text>
							</paragraph><paragraph id="ID0de7549db58247dc8be655d8396a7723"><enum>(4)</enum><text>any other entity
				with significant experience and expertise in treating survivors of childhood
				cancers.</text>
							</paragraph></subsection><subsection id="IDd9c1b18cfa7149748cd92dfa4286e47d"><enum>(c)</enum><header>Use of
				funds</header><text>The Secretary may make a grant under this section to an
				eligible entity only if the entity agrees—</text>
							<paragraph id="IDaf4542df3fac45d4af2f90a6e1bbb56d"><enum>(1)</enum><text>to use the grant
				to establish a pilot program to develop, study, or evaluate one or more model
				systems for monitoring and caring for cancer survivors; and</text>
							</paragraph><paragraph id="IDc7bbaee3400b4e4aa151984c073818f2"><enum>(2)</enum><text>in developing,
				studying, and evaluating such systems, to give special emphasis to—</text>
								<subparagraph id="ID844e28944a0b4e26867408d613485b89"><enum>(A)</enum><text>the design of
				protocols for different models of follow-up care, monitoring, and other
				survivorship programs (including peer support and mentoring programs);</text>
								</subparagraph><subparagraph id="ID07c36e1e7b76410493f15877ebd72a61"><enum>(B)</enum><text>the development
				of various models for providing multidisciplinary care;</text>
								</subparagraph><subparagraph id="IDd55e119cf56a49f993a285caadc11eb3"><enum>(C)</enum><text>the dissemination
				of information and the provision of training to health care providers about how
				to provide linguistically and culturally competent follow-up care and
				monitoring to cancer survivors and their families;</text>
								</subparagraph><subparagraph id="ID54067468e97b401c86fb775c2ec7c80c"><enum>(D)</enum><text>the development
				of support programs to improve the quality of life of cancer survivors;</text>
								</subparagraph><subparagraph id="ID5f6da443db014d6a890e7dff6af6e8b7"><enum>(E)</enum><text>the design of
				systems for the effective transfer of treatment information and care summaries
				from cancer care providers to other health care providers (including risk
				factors and a plan for recommended follow-up care);</text>
								</subparagraph><subparagraph id="IDa14145041b484ee087943608480a8807"><enum>(F)</enum><text>the dissemination
				of the information and programs described in subparagraphs (A) through (E) to
				other health care providers (including primary care physicians and internists)
				to cancer survivors and their families, where appropriate; and</text>
								</subparagraph><subparagraph id="IDb3788e7de22742a3a737dbc8bfb0fa14"><enum>(G)</enum><text>the development
				of initiatives that promote the coordination and effective transition of care
				between cancer care providers, primary care physicians, and mental health
				professionals.</text>
								</subparagraph></paragraph></subsection><subsection commented="no" id="ID5db6d06c92684525ab01349f9a833537"><enum>(d)</enum><header>Authorization
				of appropriations</header><text>There are authorized to be appropriated to
				carry out this section $15,000,000 for each of fiscal years 2014 through
				2018.</text>
						</subsection></section><section id="ID2cc4f38016234638a747da485b22d6fd"><enum>417H–1.</enum><header>Workforce
				development collaborative on medical and psychosocial care for childhood cancer
				survivors</header>
						<subsection id="IDa79233250f494786ab36b2e0d3f93589"><enum>(a)</enum><header>In
				general</header><text>Not later than 1 year after the date of enactment of the
				<short-title>Pediatric, Adolescent, and Young Adult Cancer
				Survivorship Research and Quality of Life Act of 2013</short-title>, the
				Secretary may convene a Workforce Development Collaborative on Medical and
				Psychosocial Care for Pediatric Cancer Survivors (referred to in this section
				as the <term>Collaborative</term>). The Collaborative shall be a
				cross-specialty, multidisciplinary group composed of educators, consumer and
				family advocates, and providers of psychosocial and biomedical health
				services.</text>
						</subsection><subsection id="ID7bcc74092089425c83b327278f922acf"><enum>(b)</enum><header>Goals and
				reports</header><text>The Collaborative shall submit to the Secretary a report
				establishing a plan to meet the following objectives for medical and
				psychosocial care workforce development:</text>
							<paragraph id="ID18dc282c35794760b8bd64131797f12f"><enum>(1)</enum><text>Identifying,
				refining, and broadly disseminating to healthcare educators information about
				workforce competencies, models, and preservices curricula relevant to providing
				medical and psychosocial services to individuals with pediatric cancers.</text>
							</paragraph><paragraph id="IDc27070179fa74df496808b18b744c41a"><enum>(2)</enum><text>Adapting
				curricula for continuing education of the existing workforce using efficient
				workplace-based learning approaches.</text>
							</paragraph><paragraph id="IDb3eb8013bf674febaf6e3bdbda98b7c6"><enum>(3)</enum><text>Developing the
				skills of faculty and other trainers in teaching psychosocial health care using
				evidence-based teaching strategies.</text>
							</paragraph><paragraph id="ID7c75fb2f7a254062bebc98dee9767ac4"><enum>(4)</enum><text>Strengthening the
				emphasis on psychosocial healthcare in educational accreditation standards and
				professional licensing and certification exams by recommending revisions to the
				relevant oversight organizations.</text>
							</paragraph><paragraph id="ID8216a6a254d74d5ca16ca581541e13a8"><enum>(5)</enum><text>Evaluating the
				effectiveness of patient navigators in pediatric cancer survivorship
				care.</text>
							</paragraph><paragraph id="IDb26c558059d74126a2994aaa3271dcc4"><enum>(6)</enum><text>Evaluating the
				effectiveness of peer support programs in the psychosocial care of pediatric
				cancer patients and survivors.</text>
							</paragraph></subsection><subsection commented="no" id="id6086BF4484484E198C167007EB82765E"><enum>(c)</enum><header>Authorization
				of appropriations</header><text>There are authorized to be appropriated to
				carry out this section $5,000,000 for each of fiscal years 2014 through
				2018.</text>
						</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection commented="no" id="ID7940d098848a4fc882393a0773d2187a"><enum>(b)</enum><header>Technical
			 amendment</header>
				<paragraph commented="no" id="IDc5abd11abd86453ca8419e4f0b04d1af"><enum>(1)</enum><header>In
			 general</header><text>Section 3 of the Hematological Cancer Research Investment
			 and Education Act of 2002 (<external-xref legal-doc="public-law" parsable-cite="pl/107/172">Public Law 107–172</external-xref>; 116 Stat. 541) is amended by
			 striking <quote>section 419C</quote> and inserting <quote>section
			 417C</quote>.</text>
				</paragraph><paragraph commented="no" id="ID66dc429958cf4d099666f7d497c12b0b"><enum>(2)</enum><header>Effective
			 date</header><text>The amendment made by paragraph (1) shall take effect as if
			 included in section 3 of the Hematological Cancer Research Investment and
			 Education Act of 2002 (<external-xref legal-doc="public-law" parsable-cite="pl/107/172">Public Law 107–172</external-xref>; 116 Stat. 541).</text>
				</paragraph></subsection></section></legis-body>
</bill>


